Can Serum Glypican-3 Be a Biomarker for Effective Diagnosis of Hepatocellular Carcinoma? A Meta-Analysis of the Literature

Table 2

Patients enrolled in the selected studies used for meta-analysis.

Author (ref.)	Case	Control	TP	FP	FN	TN
Yu et al. [10]	192	101	104	1	88	100
Lee et al. [11]	120	40	65	14	55	26
Badr et al. [12]	30	30	30	2	0	28
Li et al. [13]	605	25	330	5	275	20
Chen et al. [14]	155	440	62	27	93	413
Abdelgawad et al. [15]	40	20	38	1	2	19
Gomaa et al. [16]	31	30	28	1	3	29
Wang et al. [17]	78	97	28	44	50	53
Qiao et al. [18]	101	88	52	6	49	82
Abd El Moety et al. [19]	10	40	10	24	0	16
Zhang et al. [20]	36	93	33	0	3	56
Youssef et al. [21]	40	40	33	2	7	38
Liu et al. [22]	75	32	35	2	40	30
Tangkijvanich et al. [23]	100	100	53	1	47	99
Beale et al. [24]	50	41	34	22	16	19
Hippo et al. [25]	69	38	35	4	34	34
Nakatsura et al. [26]	40	50	16	0	24	50
Capurro et al. [27]	34	91	18	1	16	90
Wang et al. [28]	84	173	NA	NA	NA	NA
Nault et al. [29]	125	170	NA	NA	NA	NA
Özkan et al. [30]	75	55	NA	NA	NA	NA
Yasuda et al. [31]	200	200	NA	NA	NA	NA

TP: true positive; FP: false positive; TN: true negative; FN: false negative; NA: data are not available.